NASDAQ:ENTA Enanta Pharmaceuticals Q2 2025 Earnings Report $5.44 -0.51 (-8.57%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$5.45 +0.01 (+0.11%) As of 05/5/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Enanta Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$1.16Beat/MissN/AOne Year Ago EPSN/AEnanta Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$15.96 millionBeat/MissN/AYoY Revenue GrowthN/AEnanta Pharmaceuticals Announcement DetailsQuarterQ2 2025Date5/5/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Enanta Pharmaceuticals Earnings HeadlinesEnanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to AnalystsMay 5 at 6:13 PM | insidermonkey.comEnanta Pharmaceuticals (ENTA) Projected to Post Earnings on MondayMay 4 at 1:37 AM | americanbankingnews.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 6, 2025 | Brownstone Research (Ad)Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average PT from AnalystsMay 3 at 2:33 AM | americanbankingnews.comClever Leaves (NASDAQ:CLVR) vs. Enanta Pharmaceuticals (NASDAQ:ENTA) Head to Head AnalysisApril 26, 2025 | americanbankingnews.comEnanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025April 8, 2025 | businesswire.comSee More Enanta Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enanta Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enanta Pharmaceuticals and other key companies, straight to your email. Email Address About Enanta PharmaceuticalsEnanta Pharmaceuticals (NASDAQ:ENTA), a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.View Enanta Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Warning or Opportunity After Super Micro Computer's EarningsAmazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Upcoming Earnings Fortinet (5/7/2025)ARM (5/7/2025)DoorDash (5/7/2025)AppLovin (5/7/2025)MercadoLibre (5/7/2025)Lloyds Banking Group (5/7/2025)Manulife Financial (5/7/2025)Novo Nordisk A/S (5/7/2025)Uber Technologies (5/7/2025)Johnson Controls International (5/7/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
